Aldeyra Therapeutics has been granted a patent for a method to treat diseases involving aldehyde toxicity. The method involves administering a primary amine compound to scavenge toxic aldehydes like MDA and HNE. This treatment can be used for various conditions including ocular, skin, autoimmune, inflammatory, neurological, and cardiovascular diseases. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aldeyra Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of January 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of diseases involving aldehyde toxicity using primary amines

Source: United States Patent and Trademark Office (USPTO). Credit: Aldeyra Therapeutics Inc

A recently granted patent (Publication Number: US11845722B2) discloses a method for treating diseases, disorders, or conditions where aldehyde toxicity is involved. The method involves administering a compound of Formula II-A or II-B either topically or systemically to the subject in need. The compound can also be a pharmaceutically acceptable salt of Formula II-A, with the possibility of deuterium enrichment in certain positions of the compound.

The patent covers a wide range of diseases and conditions that can be treated using the disclosed method. These include ocular disorders such as macular degeneration, Stargardt disease, dry eye syndrome, and various other conditions affecting the eyes. Additionally, skin diseases like psoriasis, lupus, dermatitis, and Sjogren-Larsson Syndrome are also included. Furthermore, autoimmune, immune-mediated, inflammatory, cardiovascular, neurological diseases, as well as diabetes, metabolic syndrome, and fibrotic diseases like lupus, asthma, rheumatoid arthritis, Parkinson's disease, and Alzheimer's disease are part of the scope of the patent. The method aims to address the underlying aldehyde toxicity implicated in these conditions, offering a potentially novel approach to treatment.

To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies